The role of topical cyclo-oxygenase-2 inhibitors in skin cancer: Treatment and prevention

American Journal of Clinical Dermatology

Volumn 8, Issue 4, 2007, Pages 195-200

  Zhan, Huichun ^a,b   Zheng, Haoyi ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; FLUOROURACIL; HYALURONIC ACID; IMIQUIMOD; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB;

ACTINIC KERATOSIS; CARCINOGENESIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DRUG BIOAVAILABILITY; DRUG RELEASE; DRUG WITHDRAWAL; DRY SKIN; FOLLOW UP; HUMAN; HYPERPLASIA; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PRURITUS; REVIEW; SIDE EFFECT; SKIN REDNESS; SQUAMOUS CELL CARCINOMA; SUNBURN; ULTRAVIOLET IRRADIATION; ULTRAVIOLET RADIATION; UPREGULATION;

ADMINISTRATION, TOPICAL; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; HUMANS; KERATOSIS; NEOPLASMS, SQUAMOUS CELL; SKIN; SKIN NEOPLASMS; ULTRAVIOLET RAYS;

EID: 34547575228     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200708040-00002     Document Type: Review

References (67)

1. Johnson TM, Dolan OM, Hamilton TA, et al. Clinical and histologic trends of melanoma. J Am Acad Dermatol May 1998; 38 (5 Pt 1): 681-6
2. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001 Mar 29; 344 (13): 975-83
3. Karagas MR, Stukel TA, Greenberg ER, et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer: Skin Cancer Prevention Study Group. JAMA 1992 Jun 24; 267 (24): 3305-10
4. Marcil I, Stern RS. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch Dermatol Dec 2000; 136 (12): 1524-30
5. Frankel DH, Hanusa BH, Zitelli JA. New primary nonmelanoma skin cancer in patients with a history of squamous cell carcinoma of the skin: implications and recommendations for follow-up. J Am Acad Dermatol 1992 May; 26 (5 Pt 1): 720-6
6. Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet C Semin Med Genet 2004 Nov 15; 131C (1): 82-92
7. Dodson JM, DeSpain J, Hewett JE, et al. Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective. Arch Dermatol 1991 Jul; 127 (7): 1029-31
8. Czarnecki D, Meehan CJ, Bruce F, et al. The majority of cutaneous squamous cell carcinomas arise in actinic keratoses. J Cutan Med Surg 2002 May-Jun; 6 (3): 207-9
9. Jeffes 3rd EW, Tang EH. Actinic keratosis: current treatment options. Am J Clin Dermatol 2000 May-Jun; 1 (3): 167-79
10. Marks R. Solar keratoses. Br J Dermatol 1990 Apr; 122 Suppl. 35: 49-54
11. Brash DE, Ziegler A, Jonason AS, et al. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc 1996 Apr; 1 (2): 136-42
12. Nickoloff BJ, Qin JZ, Chaturvedi V, et al. Life and death signaling pathways contributing to skin cancer. J Investig Dermatol Symp Proc 2002 Dec; 7 (1): 27-35
13. Berhane T, Halliday GM, Cooke B, et al. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002 May; 146 (5): 810-5
14. Nakagawa K, Yamamura K, Maeda S, et al. Bcl-2 expression in epidermal keratinocytic diseases. Cancer 1994 Sep 15; 74 (6): 1720-4
15. Mann JR, Backlund MG, DuBois RN. Mechanisms of disease: inflammatory mediators and cancer prevention. Nat Clin Pract Oncol 2005 Apr; 2 (4): 202-10
16. Wang D, DuBois RN. Prostaglandins and cancer. Gut 2006 Jan; 55 (1): 115-22
17. Lee JL, Mukhtar H, Bickers DR, et al. Cyclooxygenases in the skin: pharmacological and toxicological implications. Toxicol Appl Pharmacol 2003 Nov 1; 192 (3): 294-306
18. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996 Dec 27; 271 (52): 33157-60
19. Leong J, Hughes-Fulford M, Rakhlin N, et al. Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. Exp Cell Res 1996 Apr 10; 224 (1): 79-87
20. Muller-Decker K, Reinerth G, Krieg P, et al. Prostaglandin-H-synthase isozyme expression in normal and neoplastic human skin. Int J Cancer 1999 Aug 27; 82 (5): 648-56
21. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998 May; 19 (5): 723-9
22. Isoherranen K, Punnonen K, Jansen C, et al. Ultraviolet irradiation induces cyclooxygenase-2 expression in keratinocytes. Br J Dermatol 1999 Jun; 140 (6): 1017-22
23. Gresham A, Masferrer J, Chen X, et al. Increased synthesis of high-molecular-weight cPLA2 mediates early UV-induced PGE2 in human skin. Am J Physiol 1996 Apr; 270 (4 Pt 1): C1037-50
24. Wilgus TA, Parrett ML, Ross MS, et al. Inhibition of ultraviolet light B-induced cutaneous inflammation by a specific cyclooxygenase-2 inhibitor. Adv Exp Med Biol 2002; 507: 85-92
25. Wilgus TA, Ross MS, Parrett ML, et al. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. Prostaglandins Other Lipid Mediat 2000 Oct; 62 (4): 367-84
26. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 2003 Jun; 169 (6): 2352-9
27. Oshima M, Dinchuk JE, Kargman SL, et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996 Nov 29; 87 (5): 803-9
28. Liu CH, Chang SH, Narko K, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001 May 25; 276 (21): 18563-9
29. Athar M, An KP, Morel KD, et al. Ultraviolet B (UVB)-induced cox-2 expression in murine skin: an immunohistochemical study. Biochem Biophys Res Commun 2001 Feb 2; 280 (4): 1042-7
30. Muller-Decker K, Neufang G, Berger I, et al. Transgenic cyclooxygenase-2 over-expression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A 2002 Sep 17; 99 (19): 12483-8
31. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002 Jul; 76 (1): 73-80
32. Tiano HF, Loftin CD, Akunda J, et al. Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res 2002 Jun 15; 62 (12): 3395-401
33. Neufang G, Furstenberger G, Heidt M, et al. Abnormal differentiation of epidermis in transgenic mice constitutively expressing cyclooxygenase-2 in skin. Proc Natl Acad Sci U S A 2001 Jun 19; 98 (13): 7629-34
34. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995 Nov 3; 83 (3): 493-501
35. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998 Oct 1; 58 (19): 4245-9
36. Sheng H, Shao J, Morrow JD, et al. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998 Jan 15; 58 (2): 362-6
37. Arico S, Pattingre S, Bauvy C, et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002 Aug 2; 277 (31): 27613-21
38. Friedman ES, LaNatra N, Stiller MJ. NSAIDs in dermatologic therapy: review and preview. J Cutan Med Surg 2002 Sep-Oct; 6 (5): 449-59
39. Black AK, Greaves MW, Hensby CN. The anti-inflammatory and pharmacological effects of topically applied flurbiprofen on human skin 24 hours after ultraviolet B irradiation. Prostaglandins Med 1980 Nov; 5 (5): 405-13
40. Snyder DS, Eaglstein WH. Topical indomethacin and sunburn. Br J Dermatol 1974 Jan; 90 (1): 91-3
41. Butler GJ, Neale R, Green AC, et al. Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. J Am Acad Dermatol 2005 Dec; 53 (6): 966-72
42. Gupta AK, Cooper EA, Feldman SR, et al. A survey of office visits for actinic keratosis as reported by NAMCS, 1990-1999: National Ambulatory Medical Care Survey. Cutis 2002 Aug; 70 (2 Suppl.): 8-13
43. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001 Feb; 296 (2): 558-66
44. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. Arch Dermatol 1997 Oct; 133 (10): 1239-42
45. Nelson C, Rigel D, Smith S, et al. Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). J Drugs Dermatol 2004 Jul-Aug; 3 (4): 401-7
46. Wolf Jr JE, Taylor JR, Tschen E, et al. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001 Nov; 40 (11): 709-13
47. Rivers JK, Arlette J, Shear N, et al. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. Br J Dermatol 2002 Jan; 146 (1): 94-100
48. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. Australas J Dermatol 2003 Feb; 44 (1): 40-3
49. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002 Mar; 190 (3): 279-86
50. Muller-Decker K, Kopp-Schneider A, Marks F, et al. Localization of prostaglandin H synthase isoenzymes in murine epidermal tumors: suppression of skin tumor promotion by inhibition of prostaglandin H synthase-2. Mol Carcinog 1998 Sep; 23 (1): 36-44
51. Pentland AP, Schoggins JW, Scott GA, et al. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999 Oct; 20 (10): 1939-44
52. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999 Aug; 25 (4): 231-40
53. Orengo IF, Gerguis J, Phillips R, et al. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 2002 Jun; 138 (6): 751-5
54. Wilgus TA, Koki AT, Zweifel BS, et al. Chemotherapeutic efficacy of topical celecoxib in a murine model of ultraviolet light B-induced skin cancer. Mol Carcinog 2003 Sep; 38 (1): 33-9
55. Tober KL, Wilgus TA, Kusewitt DF, et al. Importance of the EP(1) receptor in cutaneous UVB-induced inflammation and tumor development. J Invest Dermatol 2006 Jan; 126 (1): 205-11
56. Mazieres B. Topical ketoprofen patch. Drugs R D 2005; 6 (6): 337-44
57. Yener G, Gonullu U, Uner M, et al. Effect of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin. Pharmazie 2003 May; 58 (5): 330-3
58. Subramanian N, Ghosal SK, Moulik SP. Enhanced in vitro percutaneous absorption and in vivo anti-inflammatory effect of a selective cyclooxygenase inhibitor using microemulsion. Drug Dev Ind Pharm 2005 May; 31 (4-5): 405-16
59. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001 Jan 1; 61 (1): 303-8
60. Kuzbicki L, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006 Feb; 16 (1): 29-36
61. Gogas H, Polyzos A, Stavrinidis I, et al. Temozolomide in combination with celecoxib in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2006 Dec; 17 (12): 1835-41
62. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003 Nov; 52 (5): 377-82
63. Lejeune FJ, Monnier Y, Ruegg C. Complete and long-lasting regression of disseminated multiple skin melanoma metastases under treatment with cyclooxygenase-2 inhibitor. Melanoma Res 2006 Jun; 16 (3): 263-5
64. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 Mar 17; 352 (11): 1092-102
65. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005 Mar 17; 352 (11): 1071-80
66. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005 Mar 17; 352 (11): 1081-91
67. Jarvis B, Figgitt DP. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Am J Clin Dermatol 2003; 4 (3): 203-13